Effect of Everolimus on the Cardiac Function in Kidney Transplant Recipients.
1Surgery, Tomishiro Central Hospital, Tomishiro-shi, Okinawa, Japan
2Urology, Kidney Center, Tokyo Women's Medical University, Shinjuku-ku, Tokyo, Japan
Meeting: 2017 American Transplant Congress
Abstract number: D106
Keywords: Immunosuppression, Kidney transplantation
Session Information
Session Name: Poster Session D: Kidney Immunosuppression: Novel Regimens and Drug Minimization
Session Type: Poster Session
Date: Tuesday, May 2, 2017
Session Time: 6:00pm-7:00pm
Presentation Time: 6:00pm-7:00pm
Location: Hall D1
PURPOSE: In this study, we evaluated the effect of everolimus (EVR), one of the mammalian targets of rapamycin on cardiac function in kidney transplant recipients.
METHODS:We retrospectively studied 87 participants who underwent kidney transplantation (KTx) between March 2009 and November 2017. All participants received tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone for maintenance immunosuppression after KTx. To standardize EVR administration at our institution, the following criteria were used: (1) The recipient did not have donor-specific antigen before KTx. (2) The recipient did not have proteinuria and uncontrollable hyperlipidemia after KTx. (3) Acute rejection was not observed on protocol biopsy 3 months after KTx. According to these criteria, we included EVR administration for maintenance immunosuppression after KTx. We compared the cardiac function of the group receiving treatment with EVR (n=34) and the non-treatment group (n=53). All participants underwent echocardiography before KTx and every year after KTx.
RESULTS:The characteristics of the 2 groups did not differ significantly (Table 1.). The mean observation period of the treatment and non-treatment group was 43.6 ± 16.1 and 45.3 ± 21.8 months, respectively (p=0.698). The mean ejection fraction (EF), fractional shortening (FS), and E-wave/A-wave (E/A) ratio of the treatment and non-treatment groups after KTx was 66.3 ± 7.5 % vs. 69.7 ± 5.5 % (p=0.018), 37.0 ± 5.9 % vs. 39.4 ± 4.7 % (p=0.036), and 1.05 ± 0.43 % vs. 0.99 ± 0.34 % (p=0.450), respectively.
| Table 1 Patient Characteristics (Mean±SD) | |||
| Treatment group (n=34) | Non-treatment group (n=53) | p- value | |
| Male, n (%) | 25 (73.5%) | 34 (64.2%) | 0.361 |
| Age (years) | 49.4 ± 13.8 | 49.4 ± 12.5 | 0.986 |
| Scr before KTx (mg/dL) | 10.5 ± 3.7 | 11.4 ± 3.8 | 0.312 |
| EF before KTx (%) | 65.4 ± 7.8 | 65.0 ± 8.7 | 0.835 |
| FS before KTx (%) | 36.3 ± 5.6 | 36.0 ± 6.3 | 0.824 |
| E/A ratio before KTx | 1.02 ± 0.36 | 0.97 ± 0.34 | 0.566 |
| Scr, serum creatinine; EF, ejection fraction; FS, fractional shortening; E/A ratio, E-wave/A-wave | |||
CONCLUSIONS: Supplementary administration of EVR after KTx may not affect cardiac diastolic function, but may reduce cardiac systolic function.
CITATION INFORMATION: Tsujimura K, Ota M, Ishida H, Tanabe K. Effect of Everolimus on the Cardiac Function in Kidney Transplant Recipients. Am J Transplant. 2017;17 (suppl 3).
To cite this abstract in AMA style:
Tsujimura K, Ota M, Ishida H, Tanabe K. Effect of Everolimus on the Cardiac Function in Kidney Transplant Recipients. [abstract]. Am J Transplant. 2017; 17 (suppl 3). https://atcmeetingabstracts.com/abstract/effect-of-everolimus-on-the-cardiac-function-in-kidney-transplant-recipients/. Accessed May 17, 2025.« Back to 2017 American Transplant Congress